Table 2.
Antiphospholipid antibody (aPL) positive sera tested by enzyme-linked immunosorbent immunoassay (ELISA) and line immunoassay (LIA) in 61 patients with antiphospholipid syndrome (APS) and 146 controls
| ELISA | LIA | LA | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aCL | aß2GPI | Any aPL | aCL | aPA | aPC | aPE | aPG | aPI | aPS | aAnV | aß2GPI | aPT | any aPL | ||||||||||||||
| G | M | G | M | G/M | G | M | G | M | G | M | G | M | G | M | G | M | G | M | G | M | G | M | G | M | G/M | ||
| APS n = 61 |
45 | 31 | 31 | 29 | 46 | 45 | 26 | 31 | 25 | 0 | 0 | 0 | 11 | 18 | 12 | 25 | 16 | 43 | 28 | 3 | 4 | 38 | 29 | 8 | 11 | 53 | 52 |
| PAPS n = 34 |
31 | 21 | 21 | 20 | 31 | 29 | 18 | 20 | 18 | 0 | 0 | 0 | 7 | 13 | 10 | 17 | 11 | 29 | 20 | 1 | 3 | 25 | 19 | 6 | 6 | 31 | 29 |
| PAPS/T n = 29 |
27 | 18 | 17 | 17 | 27 | 25 | 15 | 17 | 15 | 0 | 0 | 0 | 4 | 11 | 9 | 13 | 10 | 25 | 17 | 1 | 2 | 21 | 16 | 5 | 4 | 26 | 24 |
| PAPS/TO n = 5 |
4 | 3 | 4 | 3 | 4 | 4 | 3 | 3 | 3 | 0 | 0 | 0 | 3 | 2 | 1 | 4 | 1 | 4 | 3 | 0 | 1 | 4 | 3 | 1 | 2 | 5 | 5 |
| OAPS n = 22 |
11§ | 8 | 8 | 8 | 12§ | 13§ | 7 | 8 | 6 | 0 | 0 | 0 | 4 | 4 | 2 | 7 | 4 | 11§ | 7 | 2 | 1 | 10 | 8 | 1 | 4 | 18 | 19 |
| SAPS n = 5 |
3 | 2 | 2 | 1 | 3 | 3 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 3 | 1 | 0 | 0 | 3 | 2 | 1 | 1 | 4 | 4 |
| aPL + n = 24 |
13 | 9 | 7 | 6 | 17 | 6** | 6 | 6*** | 6 | 0 | 0 | 0 | 0* | 3 | 1 | 4* | 3 | 5** | 6 | 0 | 2 | 8* | 10 | 1 | 1 | 17 | 20 |
| IDC n = 50 |
3** | 1** | 0** | 0** | 4** | 0** | 0** | 0** | 0** | 0 | 0 | 0 | 0* | 0** | 0* | 0** | 1* | 0** | 0** | 2 | 10* | 0** | 1** | 1* | 4 | 16** | nd |
| VDRL + n = 23 |
13 | 8 | 3* | 1* | 15 | 7* | 9 | 0** | 1* | 0 | 0 | 0 | 1 | 0* | 1* | 0* | 1* | 0** | 1* | 1 | 2 | 0** | 2* | 0 | 5 | 12* | nd |
| HS n = 49 |
0** | 2** | 0** | 0** | 2** | 1** | 1** | 1** | 0** | 0 | 0 | 0 | 4 | 0** | 0* | 1** | 0** | 1** | 0** | 0 | 0 | 0** | 0** | 0* | 0* | 6** | nd |
*P < 0.05 and **p < 0.0001 for comparison of prevalence of aPL in patients with APS (n = 61) and the respective control cohort; ***trend towards difference in prevalence of aPL in patients with APS (n = 61) and the respective control cohort (p = 0.05). § P < 0.05 for comparison of prevalence of aPL in PAPS/T patients (n = 29) with SAPS or OAPS patients. aAnV antiannexin V, aß2GPI antibeta2-glycoprotein I, aCL anticardiolipin, aPA antiphosphatidic acid, aPC antiphosphatidylcholine, aPE antiphosphatidylethanolamine, aPG antiphosphatidylglycerol, aPI antiphosphatidylinositol, aPL+ asymptomatic patients with autoantibodies to phospholipids, aPS antiphosphatidylserine, aPT antiprothrombin, HS healthy subjects, IDC infectious diseases controls, LA lupus anticoagulant, nd not determined, OAPS obstetric primary antiphospholipid syndrome, PAPS primary antiphospholipid syndrome, PAPST primary antiphospholipid syndrome with thrombotic events, PAPS/TO primary antiphospholipid syndrome with thrombotic and obstetric manifestations, SAPS secondary antiphospholipid syndrome, VDRL+ Venereal Disease Research Laboratory test-positive